Natural and induced antibody polyreactivity

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 10, 2015, Pages 1230-1241

  Jarossay, Annaelle ^a,b   Hadzhieva, Maya ^c   Kaveri, Srinivas V ^a,b   Lacroix Desmazes, Sébastien ^a,b   Dimitrov, Jordan D ^a,b  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Antibodies; Antibody polyreactivity; Autoimmunity; B cell malignancies; B cells; Cryptic polyreactivity; HIV 1

Indexed keywords

AUTOANTIBODY; COMPLEMENT; CROSS REACTING ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GLYCOPROTEIN GP 41; POLYREACTIVE ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LYMPHOMA; BACTERIAL INFECTION; BINDING AFFINITY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; EHRLICHIA MURIS; IMMUNE RESPONSE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; INFECTION; INTESTINE LYMPHATIC TISSUE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NEOPLASM; REVIEW; SPLENIC MARGINAL ZONE LYMPHOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS NEUTRALIZATION; COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY;

ANTIBODIES; AUTOIMMUNITY; COMMUNICABLE DISEASES; HUMANS; NEOPLASMS;

EID: 84945378898     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150716104935     Document Type: Review

References (110)

1. Michaelides, M.C.; Eisen, H.N. The strange cross-reaction of menadione (vitamin K3) and 2,4-dinitrophenyl ligands with a myeloma protein and some conventional antibodies. J. Exp. Med., 1974, 140, 687-702.
2. Eisen, H.N.; Chakraborty, A.K. Evolving concepts of specificity in immune reactions. Proc. Natl. Acad. Sci. USA, 2010, 107, 22373- 22380.
3. Van Regenmortel, M.H. From absolute to exquisite specificity. Reflections on the fuzzy nature of species, specificity and antigenic sites. J. Immunol. Methods, 1998, 216, 37-48.
4. Notkins, A.L. Polyreactivity of antibody molecules. Trends Immunol., 2004, 25, 174-179.
5. Van Regenmortel, M.H. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J. Mol. Recognit., 2014, 27, 627-639.
6. Dimitrov, J.D.; Planchais, C.; Roumenina, L.T.; Vassilev, T.L.; Kaveri, S.V.; Lacroix-Desmazes, S. Antibody polyreactivity in health and disease: Statu variabilis. J. Immunol,. 2013, 191, 993- 999.
7. Lacroix-Desmazes, S.; Kaveri, S.V.; Mouthon, L.; Ayouba, A.; Malanchere, E.; Coutinho, A.; Kazatchkine, M.D. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J. Immunol. Methods, 1998, 216, 117-137.
8. Ehrenstein, M.R.; Notley, C.A. The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol., 2010, 10, 778-786.
9. Cabiedes, J.; Cabral, A.R.; Alarcon-Segovia, D. Hidden antiphospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur. J. Immunol., 1998, 28, 2108-2114.
10. McMahon, M.J.; O'Kennedy, R. Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J. Immunol. Methods, 2000, 241, 1-10.
11. Bouvet, J.P.; Stahl, D.; Rose, S.; Quan, C.P.; Kazatchkine, M.D.; Kaveri, S.V. Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun., 2001, 16, 163-172.
12. Cheng, H.M.; Chamley, L. Cryptic natural autoantibodies and copotentiators. Autoimmun. Rev., 2008, 7, 431-434.
13. Djoumerska-Alexieva, I.K.; Dimitrov, J.D.; Voynova, E.N.; Lacroix-Desmazes, S.; Kaveri, S.V.; Vassilev, T.L. Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J., 2010, 277, 3039-3050.
14. Mouthon, L.; Haury, M.; Lacroix-Desmazes, S.; Barreau, C.; Coutinho, A.; Kazatchkine, M.D. Analysis of the normal human IgG antibody repertoire. Evidence that IgG autoantibodies of healthy adults recognize a limited and conserved set of protein antigens in homologous tissues. J. Immunol., 1995, 154, 5769- 5778.
15. McIntyre, J.A. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation--reduction reactions. Thromb. Res., 2004, 114, 579-587.
16. McIntyre, J.A.; Wagenknecht, D.R.; Faulk, W.P. Autoantibodies unmasked by redox reactions. J. Autoimmun., 2005, 24, 311-317.
17. Dimitrov, J.D.; Ivanovska, N.D.; Lacroix-Desmazes, S.; Doltchinkova, V.R.; Kaveri, S.V.; Vassilev, T.L. Ferrous ions and reactive oxygen species increase antigen-binding and anti inflammatory activities of immunoglobulin G. J. Biol. Chem., 2006, 281, 439-446.
18. Dimitrov, J.D.; Roumenina, L.T.; Doltchinkova, V.R.; Mihaylova, N.M.; Lacroix-Desmazes, S.; Kaveri, S.V.; Vassilev, T.L. Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions. J. Biol. Chem., 2007, 282, 26696-26706.
19. Dimitrov, J.D.; Vassilev, T.L.; Andre, S.; Kaveri, S.V.; Lacroix- Desmazes, S. Functional variability of antibodies upon oxidative processes. Autoimmun. Rev., 2008, 7, 574-578.
20. Mihaylova, N.M.; Dimitrov, J.D.; Djoumerska-Alexieva, I.K.; Vassilev, T.L. Inflammation-induced enhancement of IgG immunoreactivity. Inflamm. Res., 2008, 57, 1-3.
21. Zhou, Z.H.; Notkins, A.L. Polyreactive antigen-binding B (PAB-) cells are widely distributed and the PAB population consists of both B-1+ and B-1- phenotypes. Clin. Exp. Immunol., 2004, 137, 88-100.
22. Marchalonis, J.J.; Hohman, V.S.; Thomas, C.; Schluter, S.F. Antibody production in sharks and humans: A role for natural antibodies. Dev. Comp. Immunol., 1993, 17, 41-53.
23. Coutinho, A.; Kazatchkine, M.D.; Avrameas, S. Natural autoantibodies. Curr. Opin. Immunol., 1995, 7, 812-818.
24. Quan, C.P.; Berneman, A.; Pires, R.; Avrameas, S.; Bouvet, J.P. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect. Immun., 1997, 65, 3997-4004.
25. Marchalonis, J.J.; Adelman, M.K.; Robey, I.F.; Schluter, S.F.; Edmundson, A.B. Exquisite specificity and peptide epitope recognition promiscuity, properties shared by antibodies from sharks to humans. J. Mol. Recognit., 2001, 14, 110-121.
26. Casali, P.; Notkins, A.L. Probing the human B-cell repertoire with EBV: Polyreactive antibodies and CD5+ B lymphocytes, Annu. Rev. Immunol., 1989, 7, 513-535.
27. Panda, S.; Ding, J.L. Natural antibodies bridge innate and adaptive immunity. J. Immunol., 2015, 194, 13-20.
28. Cerutti, A.; Cols, M.; Puga, I. Marginal zone B cells: Virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol., 2013, 13, 118-132.
29. Manivel, V.; Sahoo, N.C.; Salunke, D.M.; Rao, K.V. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity, 2000, 13, 611-620.
30. Manivel, V.; Bayiroglu, F.; Siddiqui, Z.; Salunke, D.M.; Rao, K.V. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J. Immunol., 2002, 169, 888-897.
31. Wedemayer, G.J.; Patten, P.A.; Wang, L.H.; Schultz, P.G.; Stevens, R.C. Structural insights into the evolution of an antibody combining site. Science, 1997, 276, 1665-1669.
32. Nguyen, H.P.; Seto, N.O.; MacKenzie, C.R.; Brade, L.; Kosma, P.; Brade, H.; Evans, S.V. Germline antibody recognition of distinct carbohydrate epitopes. Nat. Struct. Biol., 2003, 10, 1019-1025.
33. Wardemann, H.; Yurasov, S.; Schaefer, A.; Young, J.W.; Meffre, E.; Nussenzweig, M.C. Predominant autoantibody production by early human B cell precursors. Science, 2003, 301, 1374-1377.
34. Tiller, T.; Tsuiji, M.; Yurasov, S.; Velinzon, K.; Nussenzweig, M. C.; Wardemann, H. Autoreactivity in human IgG+ memory B cells. Immunity, 2007, 26, 205-213.
35. Benckert, J.; Schmolka, N.; Kreschel, C.; Zoller, M.J.; Sturm, A.; Wiedenmann, B.; Wardemann, H. The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J. Clin. Invest., 2011, 121, 1946-1955.
36. Zhou, Z.H.; Tzioufas, A.G.; Notkins, A.L. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J. Autoimmun., 2007, 29, 219-228.
37. Mahendra, A.; Gangadharan, B.; Andre, S.; Boudjoghra, M.; Davi, F.; Lecerf, M.; Planchais, C.; Kaveri, S.V.; Lacroix-Desmazes, S.; Dimitrov, J.D. Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. Mol. Immunol., 2014, 60, 54-61.
38. Dimitrov, J.D.; Planchais, C.; Scheel, T.; Ohayon, D.; Mesnage, S.; Berek, C.; Kaveri, S.V.; Lacroix-Desmazes, S. A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism. J. Biol. Chem., 2014, 289, 17767-17779.
39. Ichiyoshi, Y.; Casali, P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J. Exp. Med., 1994, 180, 885-895.
40. James, L.C.; Tawfik, D.S. Conformational diversity and protein evolution--a 60-year-old hypothesis revisited. Trends Biochem. Sci., 2003, 28, 361-368.
41. Dimitrov, J.D.; Kaveri, S.V.; Lacroix-Desmazes, S. Thermodynamic stability contributes to immunoglobulin specificity. Trends Biochem. Sci., 2014, 39, 221-226.
42. Foote, J.; Milstein, C. Conformational isomerism and the diversity of antibodies. Proc. Natl. Acad. Sci. USA, 1994, 91, 10370-10374.
43. James, L.C.; Roversi, P.; Tawfik, D.S. Antibody multispecificity mediated by conformational diversity. Science, 2003, 299, 1362- 1367.
44. Sethi, D.K.; Agarwal, A.; Manivel, V.; Rao, K.V.; Salunke, D.M. Differential epitope positioning within the germline antibody paratope enhances promiscuity in the primary immune response. Immunity, 2006, 24, 429-438.
45. Corper, A.L.; Sohi, M.K.; Bonagura, V.R.; Steinitz, M.; Jefferis, R.; Feinstein, A.; Beale, D.; Taussig, M.J.; Sutton, B.J. Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nat. Struct. Biol., 1997, 4, 374-381.
46. Dimitrov, J.D.; Kaveri, S.V.; Lacroix-Desmazes, S. Gain of function of immunoglobulins after partial unfolding or cofactor binding. Mol. Immunol., 2013, 55, 195-196.
47. Dimitrov, J.D.; Lacroix-Desmazes, S.; Kaveri, S.V.; Vassilev, T.L. Transition towards antigen-binding promiscuity of a monospecific antibody. Mol. Immunol., 2007, 44, 1854-1863.
48. Djoumerska-Alexieva, I.K.; Dimitrov, J.D.; Nacheva, J.; Kaveri, S. V.; Vassilev, T.L. Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations. Autoimmunity, 2009, 42, 365-367.
49. Ochsenbein, A.F.; Zinkernagel, R.M. Natural antibodies and complement link innate and acquired immunity. Immunol. Today, 2000, 21, 624-630.
50. Ochsenbein, A.F.; Fehr, T.; Lutz, C.; Suter, M.; Brombacher, F.; Hengartner, H.; Zinkernagel, R.M. Control of early viral and bacterial distribution and disease by natural antibodies. Science, 1999, 286, 2156-2159.
51. Zhou, Z.H.; Zhang, Y.; Hu, Y.F.; Wahl, L.M.; Cisar, J.O.; Notkins, A.L. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host. Microbe., 2007, 1, 51-61.
52. Notley, C.A.; Brown, M.A.; Wright, G.P.; Ehrenstein, M.R. Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells. J. Immunol., 2011, 186, 4967-4972.
53. Elkon, K.B.; Silverman, G.J. Naturally occurring autoantibodies to apoptotic cells. Adv. Exp. Med. Biol., 2012, 750, 14-26.
54. Zhou, Z.H.; Wild, T.; Xiong, Y.; Sylvers, P.; Zhang, Y.; Zhang, L.; Wahl, L.; Wahl, S.M.; Kozlowski, S.; Notkins, A.L. Polyreactive antibodies plus complement enhance the phagocytosis of cells made apoptotic by UV-light or HIV. Sci. Rep., 2013, 3, 2271.
55. Pavlovic, S.; Zdravkovic, N.; Dimitrov, J.D.; Djukic, A.; Arsenijevic, N.; Vassilev, T.L.; Lukic, M.L. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin. Immunol., 2011, 138, 162-171.
56. Schwartz-Albiez, R. Naturally occurring antibodies directed against carbohydrate tumor antigens. Adv. Exp. Med. Biol., 2012, 750, 27- 43.
57. Vollmers, H.P.; Brandlein, S. Natural IgM antibodies: The orphaned molecules in immune surveillance. Adv. Drug Deliv. Rev., 2006, 58, 755-765.
58. Vollmers, H.P.; Brandlein, S. The "early birds": natural IgM antibodies and immune surveillance. Histol. Histopathol., 2005, 20, 927-937.
59. Larkin, J.M.; Norsworthy, P.J.; A'Hern, R.P.; Eisen, T.G.; Gore, M. E.; Porter, C.D. Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma. Melanoma. Res., 2006, 16, 157-163.
60. Brandlein, S.; Lorenz, J.; Ruoff, N.; Hensel, F.; Beyer, I.; Muller, J.; Neukam, K.; Illert, B.; Eck, M.; Muller-Hermelink, H.K.; Vollmers, H.P. Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients. Hum. Antibodies., 2002, 11, 107-119.
61. Cao, Y.; Merling, A.; Karsten, U.; Goletz, S.; Punzel, M.; Kraft, R.; Butschak, G.; Schwartz-Albiez, R. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int. J. Cancer, 2008, 123, 89-99.
62. Vollmers, H.P.; Brandlein, S. Natural human immunoglobulins in cancer immunotherapy. Immunotherapy, 2009, 1, 241-248.
63. Borche, L.; Lim, A.; Binet, J.L.; Dighiero, G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood, 1990, 76, 562-569.
64. Sthoeger, Z.M.; Wakai, M.; Tse, D.B.; Vinciguerra, V.P.; Allen, S. L.; Budman, D.R.; Lichtman, S.M.; Schulman, P.; Weiselberg, L. R.; Chiorazzi, N. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med., 1989, 169, 255-268.
65. Messmer, B.T.; Albesiano, E.; Efremov, D.G.; Ghiotto, F.; Allen, S.L.; Kolitz, J.; Foa, R.; Damle, R.N.; Fais, F.; Messmer, D.; Rai, K.R.; Ferrarini, M.; Chiorazzi, N. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med., 2004, 200, 519-525.
66. Hamblin, T.J.; Davis, Z.; Gardiner, A.; Oscier, D.G.; Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 1999, 94, 1848- 1854.
67. Herve, M.; Xu, K.; Ng, Y.S.; Wardemann, H.; Albesiano, E.; Messmer, B.T.; Chiorazzi, N.; Meffre, E. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest., 2005, 115, 1636-1643.
68. Lanemo Myhrinder, A.; Hellqvist, E.; Sidorova, E.; Soderberg, A.; Baxendale, H.; Dahle, C.; Willander, K.; Tobin, G.; Backman, E.; Soderberg, O.; Rosenquist, R.; Horkko, S.; Rosen, A. A new perspective: Molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood, 2008, 111, 3838-3848.
69. Chu, C.C.; Catera, R.; Hatzi, K.; Yan, X.J.; Zhang, L.; Wang, X. B.; Fales, H.M.; Allen, S.L.; Kolitz, J.E.; Rai, K.R.; Chiorazzi, N. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood, 2008, 112, 5122-5129.
70. Catera, R.; Silverman, G.J.; Hatzi, K.; Seiler, T.; Didier, S.; Zhang, L.; Herve, M.; Meffre, E.; Oscier, D.G.; Vlassara, H.; Scofield, R. H.; Chen, Y.; Allen, S.L.; Kolitz, J.; Rai, K.R.; Chu, C.C.; Chiorazzi, N. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol. Med., 2008, 14, 665-674.
71. Craig, V.J.; Arnold, I.; Gerke, C.; Huynh, M.Q.; Wundisch, T.; Neubauer, A.; Renner, C.; Falkow, S.; Muller, A. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood, 2010, 115, 581-591.
72. Warsame, A.A.; Aasheim, H.C.; Nustad, K.; Troen, G.; Tierens, A.; Wang, V.; Randen, U.; Dong, H.P.; Heim, S.; Brech, A.; Delabie, J. Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity. Blood, 2011, 118, 3331-3339.
73. Sungalee, S.; Mamessier, E.; Morgado, E.; Gregoire, E.; Brohawn, P.Z.; Morehouse, C.A.; Jouve, N.; Monvoisin, C.; Menard, C.; Debroas, G.; Faroudi, M.; Mechin, V.; Navarro, J.M.; Drevet, C.; Eberle, F.C.; Chasson, L.; Baudimont, F.; Mancini, S.J.; Tellier, J.; Picquenot, J.M.; Kelly, R.; Vineis, P.; Ruminy, P.; Chetaille, B.; Jaffe, E.S.; Schiff, C.; Hardwigsen, J.; Tice, D.A.; Higgs, B.W.; Tarte, K.; Nadel, B.; Roulland, S. Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. J. Clin. Invest., 2014, 124, 5337-5351.
74. Vajdic, C.M.; Landgren, O.; McMaster, M.L.; Slager, S.L.; Brooks-Wilson, A.; Smith, A.; Staines, A.; Dogan, A.; Ansell, S. M.; Sampson, J.N.; Morton, L.M.; Linet, M.S. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J. Natl. Cancer Inst. Monogr., 2014, 2014, 87-97.
75. McIntyre, J.A.; Faulk, W.P. Redox-reactive autoantibodies: Biochemistry, characterization, and specificities. Clin. Rev. Aller. Immunol., 2009, 37, 49-54.
76. Meffre, E.; Wardemann, H. B-cell tolerance checkpoints in health and autoimmunity. Curr. Opin. Immunol., 2008, 20, 632-638.
77. Rantapaa-Dahlqvist, S.; De Jong, B.A.; Berglin, E.; Hallmans, G.; Wadell, G.; Stenlund, H.; Sundin, U.; Van Venrooij, W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthriti. Arthritis. Rheum., 2003, 48, 2741-2749.
78. Samuels, J.; Ng, Y.S.; Coupillaud, C.; Paget, D.; Meffre, E. Impaired early B cell tolerance in patients with rheumatoid arthritis. J.Exp.Med., 2005, 201, 1659-1667.
79. Amara, K.; Steen, J.; Murray, F.; Morbach, H.; Fernandez- Rodriguez, B.M.; Joshua, V.; Engstrom, M.; Snir, O.; Israelsson, L.; Catrina, A.I.; Wardemann, H.; Corti, D.; Meffre, E.; Klareskog, L.; Malmstrom, V. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. J.Exp.Med., 2013, 210, 445- 455.
80. Von Budingen, H.C.; Bar-Or, A.; Zamvil, S.S. B cells in multiple sclerosis: Connecting the dots. Curr. Opin. Immunol., 2011, 23, 713-720.
81. Kinnunen, T.; Chamberlain, N.; Morbach, H.; Cantaert, T.; Lynch, M.; Preston-Hurlburt, P.; Herold, K.C.; Hafler, D.A.; O'Connor, K. C.; Meffre, E. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J.Clin.Invest., 2013, 123, 2737- 2741.
82. Janssen, E.; Morbach, H.; Ullas, S.; Bannock, J.M.; Massad, C.; Menard, L.; Barlan, I.; Lefranc, G.; Su, H.; Dasouki, M.; Al-Herz, W.; Keles, S.; Chatila, T.; Geha, R.S.; Meffre, E. Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral Bcell tolerance and defective regulatory T cells. J.AllergyClin. Immunol., 2014, 134, 1365-1374.
83. Yurasov, S.; Wardemann, H.; Hammersen, J.; Tsuiji, M.; Meffre, E.; Pascual, V.; Nussenzweig, M.C. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J.Exp.Med., 2005, 201, 703-711.
84. Yurasov, S.; Tiller, T.; Tsuiji, M.; Velinzon, K.; Pascual, V.; Wardemann, H.; Nussenzweig, M. C. Persistent expression of autoantibodies in SLE patients in remission J.Exp.Med., 2006, 203, 2255-2261.
85. Mietzner, B.; Tsuiji, M.; Scheid, J.; Velinzon, K.; Tiller, T.; Abraham, K.; Gonzalez, J. B.; Pascual, V.; Stichweh, D.; Wardemann, H.; Nussenzweig, M. C. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl. Acad. Sci. US A, 2008, 105, 9727-9732.
86. Zhang, J.; Jacobi, A.M.; Wang, T.; Berlin, R.; Volpe, B. T.; Diamond, B. Polyreactive autoantibodies in systemic lupus erythematosus have pathogenic potential J. Autoimmun., 2009, 33, 270-274.
87. Porcheray, F.; DeVito, J.; Helou, Y.; Dargon, I.; Fraser, J.W.; Nobecourt, P.; Ferdman, J.; Germana, S.; Girouard, T.C.; Kawai, T.; Saidman, S.L.; Wong, W.; Colvin, R.B.; Leguern, C.; Zorn, E. Expansion of polyreactive B cells cross-reactive to HLA and self in the blood of a patient with kidney graft rejection. Am. J. Transplant., 2012, 12, 2088-2097.
88. Porcheray, F.; Fraser, J.W.; Gao, B.; McColl, A.; DeVito, J.; Dargon, I.; Helou, Y.; Wong, W.; Girouard, T.C.; Saidman, S.L.; Colvin, R.B.; Palmisano, A.; Maggiore, U.; Vaglio, A.; Smith, R. N.; Zorn, E. Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement Am. J. Transplant., 2013, 13, 2590-2600.
89. McIntyre, J.A.; Wagenknecht, D.R.; Faulk, W.P. Redox-reactive autoantibodies: Detection and physiological relevanc. Autoimmun. Rev., 2006, 5, 76-83.
90. Omersel, J.; Zager, U.; Kveder, T.; Bozic, B. Alteration of antibody specificity during isolation and storage. J. Immunoassay Immunochem., 2010, 31, 45-59.
91. Jayasekera, J.P.; Moseman, E.A.; Carroll, M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol., 2007, 81, 3487-3494.
92. Boes, M.; Prodeus, A.P.; Schmidt, T.; Carroll, M.C.; Chen, J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med., 1998, 188, 2381- 2386.
93. Jones, D. D.; DeIulio, G.A.; Winslow, G.M. Antigen-driven induction of polyreactive IgM during intracellular bacterial infection. J. Immunol., 2012, 189, 1440-1447.
94. Balakrishnan, T.; Bela-Ong, D.B.; Toh, Y.X.; Flamand, M.; Devi, S.; Koh, M.B.; Hibberd, M.L.; Ooi, E.E.; Low, J.G.; Leo, Y.S.; Gu, F.; Fink, K. Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection. PLoSOne, 2011, 6, e29430.
95. Dejnirattisai, W.; Jumnainsong, A.; Onsirisakul, N.; Fitton, P.; Vasanawathana, S.; Limpitikul, W.; Puttikhunt, C.; Edwards, C.; Duangchinda, T.; Supasa, S.; Chawansuntati, K.; Malasit, P.; Mongkolsapaya, J.; Screaton, G. Cross-reacting antibodies enhance dengue virus infection in humans. Science, 2010, 328, 745-748.
96. Haynes, B.F.; Fleming, J.; St Clair, E.W.; Katinger, H.; Stiegler, G.; Kunert, R.; Robinson, J.; Scearce, R.M.; Plonk, K.; Staats, H. F.; Ortel, T.L.; Liao, H.X.; Alam, S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science, 2005, 308, 1906-1908.
97. Mouquet, H.; Scheid, J.F.; Zoller, M.J.; Krogsgaard, M.; Ott, R.G.; Shukair, S.; Artyomov, M.N.; Pietzsch, J.; Connors, M.; Pereyra, F.; Walker, B.D.; Ho, D.D.; Wilson, P.C.; Seaman, M.S.; Eisen, H. N.; Chakraborty, A.K.; Hope, T.J.; Ravetch, J.V.; Wardemann, H.; Nussenzweig, M.C. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.
98. Mouquet, H.; Nussenzweig, M.C. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol. Life Sci., 2012, 69, 1435-1445.
99. Mouquet, H.; Klein, F.; Scheid, J.F.; Warncke, M.; Pietzsch, J.; Oliveira, T.Y.; Velinzon, K.; Seaman, M.S.; Nussenzweig, M.C. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. PLoSOne, 2011, 6, e24078.
100. Ditzel, H.J.; Itoh, K.; Burton, D.R. Determinants of polyreactivity in a large panel of recombinant human antibodies from HIV-1 infection. J. Immunol., 1996, 157, 739-749.
101. Alam, S.M.; McAdams, M.; Boren, D.; Rak, M.; Scearce, R.M.; Gao, F.; Camacho, Z.T.; Gewirth, D.; Kelsoe, G.; Chen, P.; Haynes, B.F. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol., 2007, 178, 4424-4435.
102. Alam, S.M.; Morelli, M.; Dennison, S.M.; Liao, H.X.; Zhang, R.; Xia, S.M.; Rits-Volloch, S.; Sun, L.; Harrison, S.C.; Haynes, B.F.; Chen, B. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. USA, 2009, 106, 20234-20239.
103. Diskin, R.; Marcovecchio, P.M.; Bjorkman, P.J. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol., 2010, 17, 608-613.
104. Yang, G.; Holl, T.M.; Liu, Y.; Li, Y.; Lu, X.; Nicely, N.I.; Kepler, T.B.; Alam, S.M.; Liao, H.X.; Cain, D.W.; Spicer, L.; VandeBerg, J.L.; Haynes, B.F.; Kelsoe, G. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med., 2013, 210, 241-256.
105. Bonsignori, M.; Wiehe, K.; Grimm, S.K.; Lynch, R.; Yang, G.; Kozink, D.M.; Perrin, F.; Cooper, A.J.; Hwang, K.K.; Chen, X.; Liu, M.; McKee, K.; Parks, R.J.; Eudailey, J.; Wang, M.; Clowse, M.; Criscione-Schreiber, L.G.; Moody, M.A.; Ackerman, M.E.; Boyd, S.D.; Gao, F.; Kelsoe, G.; Verkoczy, L.; Tomaras, G.D.; Liao, H.X.; Kepler, T.B.; Montefiori, D.C.; Mascola, J.R.; Haynes, B.F. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J. Clin. Invest., 2014, 124, 1835-1843.
106. Hwang, K.K.; Trama, A.M.; Kozink, D.M.; Chen, X.; Wiehe, K.; Cooper, A.J.; Xia, S.M.; Wang, M.; Marshall, D.J.; Whitesides, J.; Alam, M.; Tomaras, G.D.; Allen, S.L.; Rai, K.R.; McKeating, J.; Catera, R.; Yan, X.J.; Chu, C.C.; Kelsoe, G.; Liao, H.X.; Chiorazzi, N.; Haynes, B.F. IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. PLoSOne, 2014, 9, e90725.
107. Chen, Y.; Zhang, J.; Hwang, K.K.; Bouton-Verville, H.; Xia, S.M.; Newman, A.; Ouyang, Y.B.; Haynes, B.F.; Verkoczy, L. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol., 2013, 191, 1260-1275.
108. Verkoczy, L.; Chen, Y.; Zhang, J.; Bouton-Verville, H.; Newman, A.; Lockwood, B.; Scearce, R.M.; Montefiori, D.C.; Dennison, S. M.; Xia, S.M.; Hwang, K.K.; Liao, H.X.; Alam, S.M.; Haynes, B. F. Induction of HIV-1 broad neutralizing antibodies in 2F5 knockin mice: selection against membrane proximal external regionassociated autoreactivity limits T-dependent responses. J. Immunol., 2013, 191, 2538-2550.
109. Robinson, W.E., JR.; Kawamura, T.; Lake, D.; Masuho, Y.; Mitchell, W.M.; Hersh, E.M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro J. Virol., 1990, 64, 5301-5305.
110. Takada, A.; Kawaoka, Y. Antibody-dependent enhancement of viral infection: Molecular mechanisms and in vivo implications. Rev. Med. Virol., 2003, 13, 387-398.